Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter SEIFEM study

被引：2

作者：

Autore, Francesco ^{[1
]}

Visentin, Andrea ^{[2
]}

Deodato, Marina ^{[3
]}

Vitale, Candida ^{[4
,5
]}

Galli, Eugenio ^{[1
]}

Fresa, Alberto ^{[1
]}

Fazzi, Rita ^{[6
]}

Sanna, Alessandro ^{[7
]}

Olivieri, Jacopo ^{[8
]}

Scortechini, Ilaria ^{[9
]}

Del Principe, Maria Ilaria ^{[10
]}

Sportoletti, Paolo ^{[11
]}

Schiattone, Luana ^{[12
]}

Maschio, Nilla ^{[13
]}

Facchinelli, Davide ^{[14
]}

Marchesi, Francesco ^{[15
]}

Coscia, Marta ^{[4
,5
]}

Tedeschi, Alessandra ^{[3
]}

Trentin, Livio ^{[2
]}

Innocenti, Idanna ^{[1
]}

Candoni, Anna ^{[8
,16
]}

Busca, Alessandro ^{[4
,5
]}

Pagano, Livio ^{[1
]}

Laurenti, Luca ^{[1
]}

机构：

[1] Fdn Policlin Univ A Gemelli IRCCS, Largo Agostino Gemelli 8, I-00168 Rome, Italy

[2] Univ Padua, Padua, Italy

[3] ASST Grande Osped Metropolitano Niguarda, Milan, Italy

[4] Univ Torino, AOU Citta Salute & Sci Torino, Turin, Italy

[5] Univ Torino, Dipartimento Biotecnol Mol & Sci Salute, Turin, Italy

[6] Azienda Osped Univ Pisana, Pisa, Italy

[7] Azienda Osped Univ Careggi, Florence, Italy

[8] Clin Ematol Udine, Udine, Italy

[9] Azienda Osped Univ Marche, Ancona, Italy

[10] Univ Roma Tor Vergata, Dipartimento Biomed & Prevenz, Rome, Italy

[11] AO Santa Maria Misericordia Perugia, Perugia, Italy

[12] Presidio Osped S Spirito Pescara, Pescara, Italy

[13] Oncoematol Ist Oncol Veneto IOV IRCCS, Padua, Italy

[14] Osped San Bortolo, Vicenza, Italy

[15] IRCCS Regina Elena Natl Canc Inst, Rome, Italy

[16] Univ Modena & Reggio Emilia, Modena, Italy

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2024年 / 99卷 / 05期

关键词：

RITUXIMAB;

D O I：

10.1002/ajh.27247

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：982 / 984

页数：3

共 39 条

[21] Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia
Elter, T.
James, R.
Busch, R.
Winkler, D.
Ritgen, M.
Boettcher, S.
Kahl, C.
Gassmann, W.
Stauch, M.
Hasan, I.
Staib, P.
Fischer, K.
Fink, A-M
Bahlo, J.
Buehler, A.
Doehner, H.
Wendtner, C-M
Stilgenbauer, S.
Engert, A.
Hallek, M.
LEUKEMIA, 2012, 26 (12) : 2549 - 2552
[22] Fixed-Duration First-Line Treatment With Ibrutinib Plus Venetoclax for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Primary Analysis of the Fixed-Duration Cohort of the Phase 2 CAPTIVATE Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (07) : 4 - 5
[23] Preclinical activity of anti-CCR7 immunotherapy in patients with high-risk chronic lymphocytic leukemia
Cuesta-Mateos, Carlos
Loscertales, Javier
Kreutzman, Anna
Colom-Fernandez, Beatriz
Portero-Sainz, Itxaso
Jose Perez-Villar, Juan
Terron, Fernando
Munoz-Calleja, Cecilia
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2015, 64 (06) : 665 - 676
[24] Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study
Wierda, William G.
Allan, John N.
Siddiqi, Tanya
Kipps, Thomas J.
Opat, Stephen
Tedeschi, Alessandra
Badoux, Xavier C.
Kuss, Bryone J.
Jackson, Sharon
Moreno, Carol
Jacobs, Ryan
Pagel, John M.
Flinn, Ian
Pak, Yvonne
Zhou, Cathy
Szafer-Glusman, Edith
Ninomoto, Joi
Dean, James P.
James, Danelle F.
Ghia, Paolo
Tam, Constantine S.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (34) : 3853 - +
[25] Dose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed or refractory high-risk chronic lymphocytic leukemia
Pileckyte, Regina
Jurgutis, Mindaugas
Valceckiene, Vilma
Stoskus, Mindaugas
Gineikiene, Egle
Sejoniene, Jurgita
Degulys, Andrius
Zvirblis, Tadas
Griskevicius, Laimonas
LEUKEMIA & LYMPHOMA, 2011, 52 (06) : 1055 - 1065
[26] Exposure-response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study
Deng, Rong
Gibiansky, Leonid
Lu, Tong
Li, Xiaobin
Lu, Dan
Li, Chunze
Girish, Sandhya
Wang, Jue
Boyer, Michelle
Shankar, Noopur
Humphrey, Kathryn
Freise, Kevin J.
Salem, Ahmed Hamed
Seymour, John F.
Kater, Arnon P.
Miles, Dale
LEUKEMIA & LYMPHOMA, 2020, 61 (01) : 56 - 65
[27] Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study
van Gelder, M.
van Oers, M. H.
Alemayehu, W. G.
Abrahamse-Testroote, M. C. J.
Cornelissen, J. J.
Chamuleau, M. E.
Zachee, P.
Hoogendoorn, M.
Nijland, M.
Petersen, E. J.
Beeker, A.
Timmers, G-J
Verdonck, L.
Westerman, M.
de Weerdt, O.
Kater, A. P.
BONE MARROW TRANSPLANTATION, 2016, 51 (06) : 799 - 806
[28] Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease
Lin, Thomas S.
Ruppert, Amy S.
Johnson, Amy J.
Fischer, Beth
Heerema, Nyla A.
Andritsos, Leslie A.
Blum, Kristie A.
Flynn, Joseph M.
Jones, Jeffrey A.
Hu, Weihong
Moran, Mollie E.
Mitchell, Sarah M.
Smith, Lisa L.
Wagner, Amy J.
Raymond, Chelsey A.
Schaaf, Larry J.
Phelps, Mitch A.
Villalona-Calero, Miguel A.
Grever, Michael R.
Byrd, John C.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) : 6012 - 6018
[29] Clinical activity of a new regimen combining gemcitabine and alemtuzumab in high-risk relapsed/refractory chronic lymphocytic leukemia patients
Oberic, Lucie
Vaillant, Willy
Hebraud, Benjamin
Recher, Christian
Suc, Etienne
Houyau, Philippe
Laurent, Guy
Ysebaert, Loic
EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 94 (01) : 37 - 42
[30] Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019
van der Straten, Lina
Levin, Mark-David
Dinnessen, Manette A. W.
Visser, Otto
Posthuma, Eduardus F. M.
Doorduijn, Jeanette K.
Langerak, Anton W.
Kater, Arnon P.
Dinmohamed, Avinash G.
BLOOD CANCER JOURNAL, 2023, 13 (01)

← 1 2 3 4 →